Sirukumab (CNTO-136) is a humanized monoclonal IgG1?? antibody targeting IL-6 (Interleukin-6). By binding to IL-6, Sirukumab inhibits IL-6-mediated signal transduction, effectively preventing the activation of transcriptional activators involved in inflammatory responses. This blockade curtails the downstream biological effects associated with IL-6 activity. Sirukumab is primarily utilized in research focused on active lupus nephritis and rheumatoid arthritis, offering significant insights into the pathophysiology and potential therapeutic interventions for these conditions.
Sirukumab (CNTO-136) is a humanized monoclonal IgG1?? antibody targeting IL-6 (Interleukin-6). By binding to IL-6, Sirukumab inhibits IL-6-mediated signal transduction, effectively preventing the activation of transcriptional activators involved in inflammatory responses. This blockade curtails the downstream biological effects associated with IL-6 activity. Sirukumab is primarily utilized in research focused on active lupus nephritis and rheumatoid arthritis, offering significant insights into the pathophysiology and potential therapeutic interventions for these conditions.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
